oxybutynin has been researched along with Itching in 15 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topical capsaicin shows efficacy in the treatment of brachioradial pruritus (BRP); however, its mechanisms of action remain unclear." | 7.88 | Application of an 8% capsaicin patch normalizes epidermal TRPV1 expression but not the decreased intraepidermal nerve fibre density in patients with brachioradial pruritus. ( Agelopoulos, K; Dieckhöfer, A; Lüling, H; Pereira, MP; Ständer, S; Steinke, S; Zeidler, C, 2018) |
| "In brachioradial pruritus and notalgia paraesthetica, the 8% capsaicin patch is a novel and effective, but cost-intense, therapy." | 7.85 | Cost-effectiveness of an 8% Capsaicin Patch in the Treatment of Brachioradial Pruritus and Notalgia Paraesthetica, Two Forms of Neuropathic Pruritus. ( Augustin, M; Dieckhöfer, AM; Gutknecht, M; Herrlein, O; Lüling, H; Ständer, S; Steinke, S; Zeidler, C, 2017) |
| "Topical capsaicin shows efficacy in the treatment of brachioradial pruritus (BRP); however, its mechanisms of action remain unclear." | 3.88 | Application of an 8% capsaicin patch normalizes epidermal TRPV1 expression but not the decreased intraepidermal nerve fibre density in patients with brachioradial pruritus. ( Agelopoulos, K; Dieckhöfer, A; Lüling, H; Pereira, MP; Ständer, S; Steinke, S; Zeidler, C, 2018) |
| "In brachioradial pruritus and notalgia paraesthetica, the 8% capsaicin patch is a novel and effective, but cost-intense, therapy." | 3.85 | Cost-effectiveness of an 8% Capsaicin Patch in the Treatment of Brachioradial Pruritus and Notalgia Paraesthetica, Two Forms of Neuropathic Pruritus. ( Augustin, M; Dieckhöfer, AM; Gutknecht, M; Herrlein, O; Lüling, H; Ständer, S; Steinke, S; Zeidler, C, 2017) |
| " This study determined whether application of the AP to three different anatomical sites (lower abdomen, buttock and upper torso) influences the pharmacokinetic profile of EE and levonorgestrel (LNG)." | 2.78 | Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ( Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013) |
| " Migraine-associated gastroparesis can impair absorption and reduce bioavailability of oral migraine medications and thereby reduce and delay therapeutic efficacy." | 2.77 | Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. ( Goldstein, J; Pierce, MW; Pugach, N; Silberstein, S; Singer, R; Smith, TR, 2012) |
| " The maximum steady-state drug concentration and area under the concentration curve from time 0 on day 5 (t = 0) to the 24-hours sample on day 6 were 514 ng/mL (95% CI 439 to 603 ng/mL) and 9." | 1.48 | A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers. ( Bhatt, A; Connolly, MP; Lewis, F, 2018) |
| "Localized neuropathic pain (LNP) is a subgroup of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain, associated with negative or positive sensory signs and/or spontaneous symptoms characteristic of NP." | 1.48 | Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. ( Chinellato, E; Del Balzo, G; Martini, A; Parolini, M; Picelli, A; Polati, E; Schweiger, V; Tamburin, S; Zanzotti, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Chancellor, M | 1 |
| Meeuwis, SH | 1 |
| van Middendorp, H | 1 |
| Lavrijsen, APM | 1 |
| Veldhuijzen, DS | 1 |
| Evers, AWM | 1 |
| Pereira, MP | 2 |
| Lüling, H | 4 |
| Dieckhöfer, A | 3 |
| Steinke, S | 4 |
| Zeidler, C | 4 |
| Ständer, S | 4 |
| Lewis, F | 1 |
| Connolly, MP | 1 |
| Bhatt, A | 1 |
| Agelopoulos, K | 1 |
| Martini, A | 1 |
| Del Balzo, G | 1 |
| Schweiger, V | 1 |
| Zanzotti, M | 1 |
| Picelli, A | 1 |
| Parolini, M | 1 |
| Chinellato, E | 1 |
| Tamburin, S | 1 |
| Polati, E | 1 |
| da Cruz, CM | 1 |
| Antunes, F | 1 |
| Martin, CM | 1 |
| Osada, N | 1 |
| Schedel, F | 1 |
| Augustin, M | 2 |
| Misery, L | 1 |
| Erfan, N | 1 |
| Castela, E | 1 |
| Brenaut, E | 1 |
| Lantéri-Minet, M | 1 |
| Lacour, JP | 1 |
| Passeron, T | 1 |
| Gutknecht, M | 1 |
| Dieckhöfer, AM | 1 |
| Herrlein, O | 1 |
| Andersen, HH | 1 |
| Marker, JB | 1 |
| Hoeck, EA | 1 |
| Elberling, J | 1 |
| Arendt-Nielsen, L | 1 |
| Smith, TR | 1 |
| Goldstein, J | 1 |
| Singer, R | 1 |
| Pugach, N | 1 |
| Silberstein, S | 1 |
| Pierce, MW | 1 |
| Stanczyk, FZ | 1 |
| Archer, DF | 1 |
| Rubin, A | 1 |
| Foegh, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months[NCT00792103] | Phase 3 | 198 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Nausea free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 143 |
Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 105 |
Phonophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 109 |
Photophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participant (Number) |
|---|---|
| NP101 | 97 |
For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin). (NCT00792103)
Timeframe: 24 hours post patch activation
| Intervention | scores on a scale (Mean) |
|---|---|
| NP101 | 1.0 |
1 review available for oxybutynin and Itching
| Article | Year |
|---|---|
Physical Medicine and Rehabilitation Role on Notalgia Paresthetica: Case Report and Treatment Review.
Topics: Adult; Anesthetics, Local; Back Pain; Exercise Therapy; Female; Humans; Hyperpigmentation; Lidocaine | 2018 |
3 trials available for oxybutynin and Itching
| Article | Year |
|---|---|
Antipruritic effect of pretreatment with topical capsaicin 8% on histamine- and cowhage-evoked itch in healthy volunteers: a randomized, vehicle-controlled, proof-of-concept trial.
Topics: Administration, Cutaneous; Antipruritics; Capsaicin; Cross-Over Studies; Double-Blind Method; Female | 2017 |
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Female; Follow-Up Stu | 2012 |
Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
Topics: Abdomen; Adult; Buttocks; Cohort Studies; Contraceptive Agents, Female; Cross-Over Studies; Drug Com | 2013 |
11 other studies available for oxybutynin and Itching
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Transdermal oxybutynin. A viewpoint by Michael Chancellor.
Topics: Administration, Cutaneous; Delayed-Action Preparations; Erythema; Humans; Mandelic Acids; Pruritus; | 2003 |
Open- and Closed-Label Placebo and Nocebo Suggestions About a Sham Transdermal Patch.
Topics: Humans; Nocebo Effect; Placebo Effect; Pruritus; Suggestion; Transdermal Patch | 2021 |
Brachioradial Pruritus and Notalgia Paraesthetica: A Comparative Observational Study of Clinical Presentation and Morphological Pathologies.
Topics: Aged; Antipruritics; Back; Capsaicin; Cervical Vertebrae; Female; Forearm; Ganglia, Spinal; Humans; | 2018 |
A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers.
Topics: Administration, Topical; Adult; Area Under Curve; Female; Headache; Healthy Volunteers; Humans; Ibup | 2018 |
Application of an 8% capsaicin patch normalizes epidermal TRPV1 expression but not the decreased intraepidermal nerve fibre density in patients with brachioradial pruritus.
Topics: Administration, Cutaneous; Aged; Antipruritics; Capsaicin; Cervical Vertebrae; Epidermis; Female; Fo | 2018 |
Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy.
Topics: Aged; Analgesics; Anesthetics, Local; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; E | 2018 |
Lessons learned from hospice care.
Topics: Aged; Aged, 80 and over; Amitriptyline; Analgesics, Opioid; Drug Monitoring; Fentanyl; Health Servic | 2013 |
Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus?
Topics: Administration, Cutaneous; Aged; Antipruritics; Capsaicin; Female; Forearm; Humans; Middle Aged; Pru | 2015 |
Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antipruritics; Capsaicin; Female; France; Humans | 2015 |
Cost-effectiveness of an 8% Capsaicin Patch in the Treatment of Brachioradial Pruritus and Notalgia Paraesthetica, Two Forms of Neuropathic Pruritus.
Topics: Antipruritics; Capsaicin; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Pain Measurement | 2017 |